- Home
- MRSN vs PHLT Comparison
MRSN vs PHLT Comparison
Compare MRSN & PHLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- PHLT
- Stock Information
- Founded
- MRSN 2001
- PHLT 1976
- Country
- MRSN United States
- PHLT United States
- Employees
- MRSN N/A
- PHLT N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- PHLT Other Consumer Services
- Sector
- MRSN Health Care
- PHLT Consumer Discretionary
- Exchange
- MRSN Nasdaq
- PHLT Nasdaq
- Market Cap
- MRSN 252.0M
- PHLT 215.3M
- IPO Year
- MRSN 2017
- PHLT N/A
- Fundamental
- Price
- MRSN $0.62
- PHLT $2.31
- Analyst Decision
- MRSN Buy
- PHLT
- Analyst Count
- MRSN 6
- PHLT 0
- Target Price
- MRSN $6.00
- PHLT N/A
- AVG Volume (30 Days)
- MRSN 7.3M
- PHLT 168.5K
- Earning Date
- MRSN 02-26-2025
- PHLT 03-11-2025
- Dividend Yield
- MRSN N/A
- PHLT N/A
- EPS Growth
- MRSN N/A
- PHLT N/A
- EPS
- MRSN N/A
- PHLT N/A
- Revenue
- MRSN $34,837,000.00
- PHLT $120,782,000.00
- Revenue This Year
- MRSN N/A
- PHLT $9.72
- Revenue Next Year
- MRSN N/A
- PHLT $9.90
- P/E Ratio
- MRSN N/A
- PHLT N/A
- Revenue Growth
- MRSN N/A
- PHLT 9.39
- 52 Week Low
- MRSN $0.56
- PHLT $2.29
- 52 Week High
- MRSN $6.28
- PHLT $4.35
- Technical
- Relative Strength Index (RSI)
- MRSN 20.37
- PHLT N/A
- Support Level
- MRSN $0.56
- PHLT N/A
- Resistance Level
- MRSN $1.45
- PHLT N/A
- Average True Range (ATR)
- MRSN 0.14
- PHLT 0.00
- MACD
- MRSN -0.06
- PHLT 0.00
- Stochastic Oscillator
- MRSN 6.49
- PHLT 0.00
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About PHLT Performant Healthcare Inc. Common Stock
Performant Healthcare Inc delivers payment integrity solutions for its healthcare payer clients.